Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Karyopharm Therapeutics Inc (NASDAQ: KPTI) was $5.55 for the day, up 1.83% from the previous closing price of $5.45. In other words, the price has increased by $1.83 from its previous closing price. On the day, 0.11 million shares were traded. KPTI stock price reached its highest trading level at $5.66 during the session, while it also had its lowest trading level at $5.3711.
Ratios:
Our analysis of KPTI’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.98 and its Current Ratio is at 1.03.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 01 ’25 when Abate Kristin sold 362 shares for $6.30 per share. The transaction valued at 2,279 led to the insider holds 10,046 shares of the business.
Paulson Richard A. sold 1,257 shares of KPTI for $8,083 on Sep 15 ’25. The President and CEO now owns 84,046 shares after completing the transaction at $6.43 per share. On Sep 15 ’25, another insider, Mano Michael, who serves as the SVP, General Counsel&Secretary of the company, sold 234 shares for $6.43 each. As a result, the insider received 1,505 and left with 21,425 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KPTI now has a Market Capitalization of 94632368 and an Enterprise Value of 318677376. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.66. Its current Enterprise Value per Revenue stands at 2.236 whereas that against EBITDA is -3.071.
Stock Price History:
The Beta on a monthly basis for KPTI is 0.24, which has changed by -0.5700197 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, KPTI has reached a high of $13.20, while it has fallen to a 52-week low of $3.51. The 50-Day Moving Average of the stock is -6.97%, while the 200-Day Moving Average is calculated to be -1.38%.
Shares Statistics:
KPTI traded an average of 169.98K shares per day over the past three months and 108930 shares per day over the past ten days. A total of 17.05M shares are outstanding, with a floating share count of 14.69M. Insiders hold about 13.87% of the company’s shares, while institutions hold 40.55% stake in the company. Shares short for KPTI as of 1763078400 were 716400 with a Short Ratio of 4.21, compared to 1760486400 on 1438931. Therefore, it implies a Short% of Shares Outstanding of 716400 and a Short% of Float of 4.22.
Earnings Estimates
. The current rating of Karyopharm Therapeutics Inc (KPTI) is the result of assessments by 2.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$1.56, with high estimates of -$1.56 and low estimates of -$1.56.
Analysts are recommending an EPS of between -$11.46 and -$12.61 for the fiscal current year, implying an average EPS of -$12.03. EPS for the following year is -$4.86, with 2.0 analysts recommending between -$4.48 and -$5.25.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 6 analysts. It ranges from a high estimate of $39.36M to a low estimate of $33.35M. As of. The current estimate, Karyopharm Therapeutics Inc’s year-ago sales were $30.54MFor the next quarter, 6 analysts are estimating revenue of $35.5M. There is a high estimate of $38.5M for the next quarter, whereas the lowest estimate is $32.5M.
A total of 6 analysts have provided revenue estimates for KPTI’s current fiscal year. The highest revenue estimate was $151.34M, while the lowest revenue estimate was $145.34M, resulting in an average revenue estimate of $147.83M. In the same quarter a year ago, actual revenue was $145.24MBased on 6 analysts’ estimates, the company’s revenue will be $152.54M in the next fiscal year. The high estimate is $172M and the low estimate is $132.26M.
